Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First Relapse”

533 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 533 results

Testing effectiveness (Phase 2)Looking for participantsNCT05463263
What this trial is testing

STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Who this might be right for
Lymphoma, B-CellLymphoma, T-Cell
Step Pharma, SAS 180
Post-approval studies (Phase 4)Study completedNCT01498887
What this trial is testing

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 347
Testing effectiveness (Phase 2)WithdrawnNCT05966233
What this trial is testing

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS
Testing effectiveness (Phase 2)Looking for participantsNCT05590689
What this trial is testing

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

Who this might be right for
Glioblastoma
Universität Münster 34
Post-approval studies (Phase 4)WithdrawnNCT05900908
What this trial is testing

Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy

Who this might be right for
Glioblastoma
GT Medical Technologies, Inc.
Not applicableLooking for participantsNCT05772559
What this trial is testing

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

Who this might be right for
Acute Myeloid LeukemiaGenetic Predisposition to Disease
Assistance Publique - Hôpitaux de Paris 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750952
What this trial is testing

Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Who this might be right for
Relapsed or Metastatic Thymic CancerFirst-line Treatment
Sun Yat-sen University 24
Early research (Phase 1)Study completedNCT05040932
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Who this might be right for
Cancer
Eucure (Beijing) Biopharma Co., Ltd 8
Early research (Phase 1)Ended earlyNCT05904236
What this trial is testing

Safety and Tolerability of Intravenous Administration of ICVB-1042

Who this might be right for
Patients With Advanced Solid Tumors
IconOVir Bio 17
Early research (Phase 1)Ended earlyNCT01238029
What this trial is testing

Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 PositiveFirst or Second Line Therapy+1 more
Sponsor GmbH 12
Testing effectiveness (Phase 2)Study completedNCT00003406
What this trial is testing

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
Cancer Treatment Centers of America 30
Early research (Phase 1)Looking for participantsNCT04243785
What this trial is testing

BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Edgewood Oncology Inc. 80
Early research (Phase 1)UnknownNCT01972750
What this trial is testing

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

Who this might be right for
First or Second Recurrence of Glioblastoma
PD Dr. Martin Glas 12
Not applicableStudy completedNCT01499147
What this trial is testing

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute LeukemiaChronic Myelogenous Leukemia+8 more
University of Illinois at Chicago 100
Early research (Phase 1)Study completedNCT00042900
What this trial is testing

Pyroxamide in Treating Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06663098
What this trial is testing

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Who this might be right for
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gruppo Oncologico Italiano di Ricerca Clinica 142
Early research (Phase 1)Study completedNCT04659629
What this trial is testing

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Who this might be right for
Solid TumorAdvanced Solid Tumor
Neurogene Inc. 59
Testing effectiveness (Phase 2)UnknownNCT05497102
What this trial is testing

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

Who this might be right for
Multiple Myeloma
Samsung Medical Center 58
Not applicableLooking for participantsNCT05203003
What this trial is testing

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 260
Testing effectiveness (Phase 2)Study completedNCT01244451
What this trial is testing

GIMEMA CLL0809 Study (BendOfa)

Who this might be right for
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; orPatients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Gruppo Italiano Malattie EMatologiche dell'Adulto 49
Load More Results